For Immediate Release


Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure

Tokyo, Japan (February 10, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that, as a result of ongoing efforts to review its global R&D structure to increase R&D productivity, the company has decided to further reorganize its R&D structure by closing its Japanese research subsidiary, Asubio Pharma Co., Ltd. (location: Kobe, Japan; hereafter, Asubio Pharma) by the end of March 2018.


Asubio Pharma has approximately 150 employees and mainly focuses on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine, conducting research based on its position a drug discovery venture within Daiichi Sankyo Group.


Under this reorganization, Daiichi Sankyo plans to transfer Asubio Pharma R&D functions and employees to other Daiichi Sankyo Group companies in Japan. We expect the integration of the venture spirit of Asubio Pharma into other Daiichi Sankyo research activities to contribute greatly to improving R&D productivity.


Further details regarding the reorganization scheme will be announced in the future.


Reference: Asubio Pharma Outline

Company Name

Asubio Pharma Co., Ltd.

Paid-in Capital

50 million yen (wholly-owned subsidiary of Daiichi Sankyo Co., Ltd.)

Foundation Date

October 16, 2009

Office Location

Chuo-ku, Kobe-shi, Hyogo Prefecture


Yoshiharu Minamitake, President & CEO

Number of Employees

About 150

Type of Business

Research of pharmaceutical